Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Nicotine
AssigneeEnVivo Pharmaceuticals, Inc.
InventorGerhard Koenig
Life of this patent
Estimating the term…
Abstract
A method for improving cognition comprising co-administering to a subject an alpha 7 agonist, or a pharmaceutically acceptable salt thereof and a tobacco-free nicotine dosage is described together with related compositions.
Claims22
A method for improving cognition and/or treating a cognitive disorder comprising co-administering to a subject a therapeutically effective amount of (1) a tobacco-free nicotine dosage;
- and (2) a compound of formula (I), or a pharmaceutically acceptable salt thereof,
- wherein
- R1 is 1-azabicyclo[2.2.2]oct-3-yl,
- R2 is hydrogen or (C1-C6)alkyl,
- R3 is hydrogen, halogen or (C1-C6)alkyl,
- A is oxygen or sulfur, and
- Z is halogen, formyl, carbamoyl, cyano, trifluoromethyl, trifluoromethoxy, nitro, amino, formamido, acetamido, (C1-C6)alkyl, (C1-C6)alkyoxy, (C1-C6)alkylthio, (C1-C6)alkylamino, heteroaryl-carbonylamino, arylcarbonylamino, (C1-C4)alkylsulfonylamino, di(arylsulfonyl)amino, (C3-C6)cycloalkylcarbonylmethyl or amino(hydroxyimino)methyl.
A pharmaceutical composition comprising (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof and a tobacco-free nicotine dosage (TFN).
A daily unit dosage pharmaceutical composition comprising 0.03 to 1.0 mg of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof, a TFN, and a pharmaceutically acceptable carrier.
A packaged pharmaceutical comprising a package containing a unit dosage pharmaceutical composition comprising (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof, and a transdermal patch comprising a tobacco-free nicotine dosage.
Dependencies are inferred from the claim text.